Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
INAB
IN8bio, Inc.
The INB-600 gamma-delta T cell engager platform suggests bispecific antibody-like T cell engagers.
|
$5.90M |
$1.93
-1.28%
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$5.89M |
$5.23
+4.18%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Core focus on autoimmune immunology therapeutics with lead asset hCDR1.
|
$5.83M |
$1.06
-0.93%
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$5.57M |
$3.88
+0.26%
|
|
SXTC
China SXT Pharmaceuticals, Inc.
SXTC manufactures TCMP products and operates GMP-compliant production lines, consistent with a contract manufacturing organization (CMO) model.
|
$5.55M |
$1.38
-2.82%
|
|
BUDZ
WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
|
$5.44M |
$0.04
|
|
CPHI
China Pharma Holdings, Inc.
Core product: generic drugs manufacturing (Helpson's portfolio in PRC).
|
$5.35M |
$1.63
-0.61%
|
|
BIXT
Bioxytran, Inc.
ProLectin-M is an oral antiviral candidate; fits the Oral Small Molecule Therapeutics category as a major product line.
|
$5.35M |
$0.07
|
|
POAI
Predictive Oncology Inc.
Biotech - Oncology focus via proprietary biobank, wet-lab validation, and AI-enabled oncology drug discovery.
|
$5.31M |
$8.06
-9.64%
|
|
CLRB
Cellectar Biosciences, Inc.
Core product category: radiopharmaceuticals developed and marketed by Cellectar as radioconjugate therapies.
|
$5.21M |
$3.27
-3.39%
|
|
SNGX
Soligenix, Inc.
ThermoVax vaccine thermostabilization platform and RiVax vaccine program place Soligenix in Vaccines.
|
$5.06M |
$1.46
-5.81%
|
|
KALA
KALA BIO, Inc.
KPI-012 is a mesenchymal stem cell secretome (MSC-S) therapy, aligning with Biotech - Cell Therapy.
|
$5.03M |
$0.77
-1.64%
|
|
PCSA
Processa Pharmaceuticals, Inc.
Processa is a oncology-focused biotech developing Next Generation Cancer therapies (NGCs), placing it squarely in Biotech - Oncology.
|
$4.62M |
$0.38
-2.42%
|
|
BZYR
Burzynski Research Institute, Inc.
Company focuses on oncology therapeutics in biotech R&D.
|
$4.47M |
$0.03
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$4.43M |
$4.36
-4.18%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
NurOwn is a proprietary autologous cell therapy platform developed by Brainstorm for ALS and related neurodegenerative indications, directly produced and administered by the company.
|
$4.24M |
$0.65
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
IDXG
Interpace Biosciences, Inc.
Interpace focuses on oncology-focused molecular diagnostics and cancer risk biomarker testing, including thyroid-related cancer risk assessment.
|
$4.12M |
$1.02
|
|
CLDI
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics directly develops cancer therapies (oncolytic virus platforms) targeting oncology indications.
|
$4.08M |
$1.50
-2.60%
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$3.25M |
$1.72
-2.00%
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$3.17M |
$0.80
+0.58%
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$2.92M |
$0.44
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Lead program targets a rare disease (Netherton Syndrome) and is developed by a biotech focused on rare diseases.
|
$2.85M |
$10.95
-3.10%
|
|
ADIL
Adial Pharmaceuticals, Inc.
Lead AUD program is a neuropsychiatric CNS therapeutic, aligning with Neuropsychiatric Drug Development.
|
$2.76M |
$0.33
-4.26%
|
|
BIOE
Bio Essence Corporation
Provides outsourced contract manufacturing (OEM) services for health-related products.
|
$2.70M |
$0.07
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$2.43M |
$0.54
-1.22%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$2.36M |
$0.15
+160.68%
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$2.33M |
$5.98
+0.93%
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$2.32M |
$0.01
|
|
BIAF
bioAffinity Technologies, Inc.
The business focuses on oncology diagnostics (early detection of lung cancer).
|
$2.23M |
$2.30
-6.12%
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$2.12M |
$0.42
-1.16%
|
|
AAGH
America Great Health
Focus on peptide/protein therapeutics as a core research and therapeutic development area.
|
$2.12M |
$0.00
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$1.98M |
$1.83
-5.67%
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is AIM ImmunoTech's flagship oncology/immunotherapy platform and is being developed with cancer indications (pancreatic and ovarian cancer) in combination with checkpoint inhibitors.
|
$1.60M |
$2.10
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.47M |
$0.03
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Lead candidate Ropidoxuridine is described as an oral small-molecule therapeutic, with additional small-molecule HDAC inhibitors in the pipeline.
|
$1.30M |
$3.11
+4.71%
|
Showing page 24 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
